Cardiovascular Effects of the Cyclooxygenase Inhibitors
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
White C yclooxyenase (COX)-2 selective inhibitors were devel- oped to create a new class of nonsteroidal antiinflammatory drugs (NSAIDs) with properties similar to those of nonselective NSAIDS but without their potential COX-1-mediated gastrointestinal toxicities.1,2 Studies of the various COX-2 selective inhibitors have shown that they are in fact associated with a significantly lower risk of upper and lower gastrointestinal complications than traditional NSAIDs, except in patients who are taking concomitant low-doses of aspirin.Recent evidence also suggests that some doses of the COX-2 selective inhibitors, and perhaps some traditional NSAIDs as well, are associated with an increased risk of adverse cardiovascular (CV) events.Reports of a higher incidence of myocardial infarction (MI) among patients with arthritis taking high doses of the COX-2 selective inhibitor rofecoxib compared with those taking the NSAID naproxen 2-4 have had heightened concerns since 2001 regarding selective COX-2 inhibitor safety.In addition, in early 2005, elevated CV event rates were reported in patients with spontaneous adenomatous polyps who were taking high doses of celecoxib compared with placebo 5 and in patients who received parenteral parecoxib followed by oral valdecoxib versus placebo immediately after coronary artery bypass graft surgery.6 This article represents a compilation of the data concerning the effects of both nonselective and selective NSAIDs on blood pressure (BP), particularly in patients with hypertension and/or on antihypertensive agents.Subsequently, the impact that the COX inhibitors have on CV events from several recent clinical trials for the treatment of arthritis or for cancer prevention, as well as from selected large observational studies, is discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., & FitzGerald, G. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003199 · Cited by 1,394
Do Nonsteroidal Anti-inflammatory Drugs Affect Blood Pressure? A Meta-Analysis
Johnson, A. G., Nguyen, T. V., & Day, R. O. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-4-199408150-00011 · Cited by 717
A Meta-analysis of the Effects of Nonsteroidal Anti-inflammatory Drugs on Blood Pressure
Pope, J. E. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.1993.00410040045007 · Cited by 527
Morgan, T. O., Anderson, A., & Bertram, D. (2000) · American Journal of Hypertension · doi:10.1016/s0895-7061(00)01204-8 · Cited by 102
Virdis, A., Colucci, R., Fornai, M., Blandizzi, C., Duranti, E., Pinto, S., Bernardini, N., Segnani, C., Antonioli, L., Taddei, S., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.077644 · Cited by 102
Izhar, M., Alausa, T., Folker, A., Hung, E., & Bakris, G. L. (2004) · Hypertension · doi:10.1161/01.hyp.0000115921.55353.e0 · Cited by 77
Cited by
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153
“The BP effect appears to be dose-dependent, involving the inhibition of COX-2 in the kidneys, with a reduction in sodium excretion and an increase in intravascular volume.(186) In contrast, low-dose aspirin does not have COX-2–inhibiting or BP-increasing effects, as indicated by results from the HOT study (Hypertensio…”
ResultSelf-citationInflamm-ageing: the role of inflammation in age-dependent cardiovascular disease
Liberale, L., Montecucco, F., Tardif, J.-C., Libby, P., & Camici, G. G. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz961 · Cited by 345
Improvement of drug safety by the use of lipid-based nanocarriers
Lim, S. B., Banerjee, A., & Önyüksel, H. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.06.002 · Cited by 324
Warner, T. D., Nylander, S., & Whatling, C. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03943.x · Cited by 245
Metadata
- Authors
- White, W. B.
- Venue
- Hypertension
- Published
- 2007-03
- Volume
- 49
- Issue
- 3
- Pages
- 408-418
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2123175521
- Cited by
- 128
- References
- 8
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiovascular Effects of the Cyclooxygenase Inhibitors. https://app.cochat.ai/papers/10.1161/01.hyp.0000258106.74139.25
- The paper
- White, W. B. (2007). Cardiovascular Effects of the Cyclooxygenase Inhibitors. Hypertension. https://doi.org/10.1161/01.hyp.0000258106.74139.25
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.